Brian J. Hennessy

Suggest Changes
Learn More
Minimal residual disease negative complete response (MRD-negative CR) provides an early marker for time to treatment failure (TTF) in CLL treated with fludarabine, cyclophosphamide, and rituximab(More)
BACKGROUND Risks that are potentially associated with long-term therapies should be assessed. OBJECTIVE The present analyses were performed to determine the risk of malignancy in patients with(More)
BACKGROUND In patients presenting with a first clinical demyelinating event that is suggestive of multiple sclerosis (MS), treatment with interferon beta can delay the occurrence of further attacks(More)
  • 1